Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: INmune Bio Inc. INMB

MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treat Cancer, Alzheimer’s Disease

INmune Bio (NASDAQ: INMB), a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease, is currently developing drug candidates INKmune and INB03, which may be used to treat cancer, and XPro1595, … Continue reading

Posted in INmune Bio Inc. INMB, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Why INmune Bio Inc. (NASDAQ: INMB) Is ‘One to Watch’

INmune Bio (NASDAQ: INMB) is a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease. An article further discussing the company reads, “Drug candidates INKmune and INB03 may be used to … Continue reading

Posted in INmune Bio Inc. INMB, MissionIRNewsBreaks | Leave a comment

INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems

INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease INmune Bio’s drug candidates include … Continue reading

Posted in INmune Bio Inc. INMB | Leave a comment

MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and … Continue reading

Posted in INmune Bio Inc. INMB, MissionIRNewsBreaks | Leave a comment

INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitational

A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, … Continue reading

Posted in INmune Bio Inc. INMB | Leave a comment

INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cancer

INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a … Continue reading

Posted in INmune Bio Inc. INMB | Leave a comment

INmune Bio Inc. (NASDAQ: INMB) is “One to Watch”

INmune Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on February 4, 2019 Public clinical-stage immunology company with programs in oncology and neurodegenerative disease INmune Bio targets large markets with unsolved problems such as resistance to checkpoint … Continue reading

Posted in INmune Bio Inc. INMB | Leave a comment

MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Ninth Annual LD Micro Invitational on June 5

INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its co-founder and CFO David Moss will present at the Ninth Annual LD Micro Invitational. The … Continue reading

Posted in INmune Bio Inc. INMB, MissionIRNewsBreaks | Leave a comment